-
公开(公告)号：US20160159901A1
公开(公告)日：2016-06-09
申请号：US14904011
申请日：2014-07-30
Applicant: GANYMED PHARMACEUTICALS AG , TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG , BIONTECH AG
Inventor： Ugur Sahin , Ozlem Tureci , Korden Walter , Meike Wagner , Maria Kreuzberg , Sabine Hacker , Stefan Jacobs
IPC: C07K16/28 , A61K33/24 , A61K31/7064 , A61K31/7048 , A61N5/10 , C07K16/30 , A61K39/395 , A61K47/48 , G01N33/574 , A61K31/337 , A61K31/5365
CPC classification number: C07K16/28 , A61K31/337 , A61K31/5365 , A61K31/7048 , A61K31/7064 , A61K33/24 , A61K39/39558 , A61K47/6851 , A61K2039/505 , A61N5/10 , C07K16/30 , C07K2317/56 , C07K2317/73 , C07K2317/732 , C07K2317/76 , G01N33/57484 , G01N33/57492 , G01N2333/705 , G01N2800/52
Abstract: The present invention provides methods for diagnosis or treatment of cancer diseases involving cancer stem cells comprising targeting CLDN6. In particular, the present invention provides a method of determining cancer stem cells comprising detecting cells expressing CLDN6, Furthermore, the present invention provides a method of treating or preventing cancer comprising inhibiting and/or eliminating cancer stem cells by administering an antibody having the ability of binding to CLDN6 to a cancer patient.
Abstract translation: 本发明提供了诊断或治疗包括靶向CLDN6的癌症干细胞的癌症疾病的方法。 特别地，本发明提供了一种确定癌症干细胞的方法，包括检测表达CLDN6的细胞。此外，本发明提供了治疗或预防癌症的方法，包括通过施用具有以下能力的抗体来抑制和/或消除癌症干细胞： 与CLDN6结合至癌症患者。
-
公开(公告)号：US09194004B2
公开(公告)日：2015-11-24
申请号：US13864411
申请日：2013-04-17
Applicant: BioNTech AG
Inventor： Ugur Sahin , Ozlem Tureci , Michael Koslowski , Gerd Helftenbein , Dirk Usener , Volker Schluter
IPC: C12Q1/68 , G01N33/574
CPC classification number: G01N33/57492 , C12Q1/6886 , C12Q2600/118 , C12Q2600/158 , G06F19/22
Abstract: The invention relates to identifying tumor-associated genetic products and encoding nucleic acids thereof. A therapy and diagnosis of diseases in which the tumor-associated genetic products are aberrantly expressed, proteins, polypeptides and peptides which are expressed in association with tumor and the encoding nucleic acids for said proteins, polypeptides and peptides are also disclosed.
-
公开(公告)号：US20150247206A1
公开(公告)日：2015-09-03
申请号：US14712233
申请日：2015-05-14
Applicant: BioNTech AG , Johannes Gutenberg-Universität Mainz
Inventor： Ugur Sahin , Ozlem Tureci , Michael Koslowski
IPC: C12Q1/68 , C07K16/40 , C07K16/28 , G01N33/574 , C12N15/113
CPC classification number: C12Q1/6886 , A61K31/7088 , A61K39/39558 , A61K47/6807 , C07K16/28 , C07K16/2866 , C07K16/40 , C07K2317/76 , C12N15/1138 , C12N15/8218 , C12N2310/11 , C12N2310/14 , C12Q2600/118 , C12Q2600/154 , C12Q2600/158 , G01N33/57484 , G01N33/57492 , G01N2333/715 , G01N2333/7158 , G01N2333/916
Abstract: The present invention relates to methods which make possible to assess and/or prognose a cancer disease, the metastatic behaviour of a cancer disease and/or the occurrence of a relapse of cancer. In particular, the methods of the invention make possible to assess and/or prognose the occurrence of cancer metastasis, in particular distant metastasis. Preferably, the methods of the invention allow to discriminate malign from benign conditions.
-
44.发明申请公开(公告)号：US20150152154A1
公开(公告)日：2015-06-04
申请号：US14457897
申请日：2014-08-12
Applicant: BioNTech AG
Inventor： Thorsten Klamp , Ugur Sahin , Ozlem Tureci , Michael Koslowski , Thomas Hiller , Jens Schumacher
IPC: C07K14/47 , A61K39/00 , C12N7/00 , C07K14/005
CPC classification number: C07K14/4748 , A61K39/0011 , A61K2039/5156 , A61K2039/523 , A61K2039/5258 , A61K2039/53 , A61K2039/57 , A61K2039/575 , A61K2039/6075 , C07K14/005 , C07K2319/00 , C07K2319/40 , C12N7/00 , C12N2730/10123 , C12N2730/10134 , C12N2730/10143 , C12N2730/10171
Abstract: The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject.
Abstract translation: 本发明涉及使用包含全部或部分乙型肝炎病毒核心抗原蛋白的嵌合蛋白和包含衍生自肿瘤相关抗原的细胞外部分的表位的氨基酸序列的肿瘤免疫治疗，特别是肿瘤免疫接种。 特别地，本发明提供了包含所述嵌合蛋白的病毒样颗粒，其可用于在受试者内针对肿瘤相关抗原，特别是针对在其表面上携带所述肿瘤相关抗原的细胞引起体液免疫应答，其中 肿瘤相关抗原是所述受试者的自身蛋白质。
-
公开(公告)号：US20240059772A1
公开(公告)日：2024-02-22
申请号：US18339837
申请日：2023-06-22
Applicant: BioNTech AG , Astellas Pharma Inc. , TRON - Translationle Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz
Inventor： Ugur Sahin , Ozlem Tureci , Korden Walter , Meike Wagner , Maria Kreuzberg , Sabine Hacker , Stefan Jacobs
IPC: C07K16/28 , G01N33/574 , A61K47/68 , A61K33/243 , A61K31/337 , A61K31/5365 , A61K31/7048 , A61K31/7064 , A61K39/395 , A61N5/10 , C07K16/30
CPC classification number: C07K16/28 , G01N33/57484 , A61K47/6851 , A61K33/243 , A61K31/337 , A61K31/5365 , A61K31/7048 , A61K31/7064 , A61K39/39558 , A61N5/10 , C07K16/30 , G01N33/57492 , G01N2800/52 , C07K2317/73 , A61K2039/505
Abstract: The present invention provides methods for diagnosis or treatment of cancer diseases involving cancer stem cells comprising targeting CLDN6. In particular, the present invention provides a method of determining cancer stem cells comprising detecting cells expressing CLDN6. Furthermore, the present invention provides a method of treating or preventing cancer comprising inhibiting and/or eliminating cancer stem cells by administering an antibody having the ability of binding to CLDN6 to a cancer patient.
-
Patent Agency Ranking
公开(公告)号：US20210324341A1
公开(公告)日：2021-10-21
申请号：US17241651
申请日：2021-04-27
Applicant: BioNTech AG , TRON - Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg Universitat Mainz
Inventor： Ugur Sahin , Marco Poleganov , Tim Beissert
IPC: C12N5/074
Abstract: Methods for effecting the de-differentiation of somatic cells to cells having stem cell characteristics, in particular pluripotency, include the steps of introducing RNA encoding factors inducing the de-differentiation of somatic cells into the somatic cells and culturing the somatic cells allowing the cells to de-differentiate.
-
公开(公告)号：US10858415B2
公开(公告)日：2020-12-08
申请号：US15113981
申请日：2014-01-29
Applicant: BioNTech AG , TRON—Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg—Universitat Mainz gemeinnutzige GmbH , Universitatsmedizin der Johannes Gutenberg—Universitat Mainz , JPT Peptide Technologies GmbH
Inventor： Ugur Sahin , Matin Daneschdar , Hans-Ulrich Schmoldt , Laura-Marie Kring (née Plum) , Markus Fiedler , Ulf Reimer , Karsten Schnatbaum
IPC: A61K38/08 , A61K38/12 , C07K5/00 , A61K38/04 , C07K7/00 , C07K16/00 , C07K17/00 , C07K14/705 , C07K7/64 , A61K39/00 , G01N33/53 , G01N33/574
Abstract: The present invention provides molecules that mimic antigenic determinants of the integral transmembrane protein claudin 18.2 (CLDN18.2). These molecules compete with CLDN18.2 for binding to a CLDN18.2 binding domain, e.g. a CLDN18.2 binding domain of an antibody, and are capable of detecting antibodies against CLDN18.2. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Furthermore, they can be used for purposes of detecting agents comprising a CLDN18.2 binding domain in biological samples as well as for purifying agents comprising a CLDN18.2 binding domain.
-
公开(公告)号：US10604568B2
公开(公告)日：2020-03-31
申请号：US14904011
申请日：2014-07-30
Applicant: BioNTech AG , Astellas Pharma Inc. , TRON-TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH
Inventor： Ugur Sahin , Ozlem Tureci , Korden Walter , Meike Wagner , Maria Kreuzberg , Sabine Hacker , Stefan Jacobs
IPC: A61K39/395 , A61K47/68 , A61K31/337 , A61K31/5365 , A61K31/7048 , A61K31/7064 , C07K16/28 , G01N33/574 , A61K33/24 , A61N5/10 , C07K16/30 , A61K39/00
Abstract: The present invention provides methods for diagnosis or treatment of cancer diseases involving cancer stem cells comprising targeting CLDN6. In particular, the present invention provides a method of determining cancer stem cells comprising detecting cells expressing CLDN6, Furthermore, the present invention provides a method of treating or preventing cancer comprising inhibiting and/or eliminating cancer stem cells by administering an antibody having the ability of binding to CLDN6 to a cancer patient.
-
公开(公告)号：US20200031898A1
公开(公告)日：2020-01-30
申请号：US16595440
申请日：2019-10-07
Applicant: BioNTech AG , TRON - Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz , Universitatsmedizin der Johannes Gutenberg-Universitat Mainz , JPT Peptide Technologies GmbH
Inventor： Ugur Sahin , Matin Daneschdar , Hans-Ulrich Schmoldt , Laura-Marie Kring (née Plum) , Markus Fiedler , Ulf Reimer , Karsten Schnatbaum
IPC: C07K14/705 , G01N33/53 , A61K39/00 , G01N33/574
Abstract: The present invention provides molecules that mimic antigenic determinants of the integral transmembrane protein claudin 18.2 (CLDN18.2). These molecules compete with CLDN18.2 for binding to a CLDN18.2 binding domain, e.g. a CLDN18.2 binding domain of an antibody, and are capable of detecting antibodies against CLDN18.2. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Furthermore, they can be used for purposes of detecting agents comprising a CLDN18.2 binding domain in biological samples as well as for purifying agents comprising a CLDN18.2 binding domain.
-
公开(公告)号：US10370433B2
公开(公告)日：2019-08-06
申请号：US15552215
申请日：2016-03-15
Applicant: BIONTECH AG
Inventor： Ugur Sahin , Joycelyn Wüstehube-Lausch , Markus Fiedler , Matin Daneschdar , Hans-Ulrich Schmoldt
Abstract: The present invention relates to the diagnosis and treatment of cancerous diseases, in particular cancerous diseases expressing Seprase (Fap-alpha; fibroblast activation protein alpha). More particularly, the invention concerns peptides targeting Seprase.
-
-
-
-
-
-
-
-
-
Search Results
81
records
(took 0.059 seconds)
